against rheumatoid arthritis and atopic dermatitis. AbbVie’s immunology treatments generate approximately 50% of total revenue, oncology products contribute about 30%, neuroscience adds roughly 10%, ...
Astria Therapeutics, Inc. ( (ATXS) ) has released its Q3 earnings. Here is a breakdown of the information Astria Therapeutics, Inc. presented ...
HealthDay on MSN1d
Breathing Dirty Air Might Raise Eczema RisksCases of the autoimmune skin condition eczema appear to rise in areas most plagued by air pollution, new research shows.
The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...
The two companies have been working together since 2017, and, in 2021, they agreed to collaborate on NM26, a bispecific ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today ann ...
Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.
Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...
The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...
Enveda Therapeutics Inc. has received U.S. IND clearance and advanced into phase I trials with ENV-294, its naturally derived anti-inflammatory.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback